This assay is much simpler than existing methods for determining the activity status of the FGL1-LAG-3 pathway and for designing and detecting new LAG-3/FGL1-related cancer immunotherapies based on patients’ circling FGL1, which might be convenient for use in clinical trials. This evidence concerns the gene FGL1 and cancer.